Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors
Jessica L. Mega, MD, and Susan E. Morano have joined the Boston Scientific Corporation board of directors.
Dr. Mega is the co-founder of Verily Life Sciences, a subsidiary of Alphabet Inc. focused on life sciences and health care. She was company’s chief medical and scientific officer from 2015 to January 2023. Prior to joining Verily, Dr. Mega served as a cardiologist at Brigham & Women’s Hospital, as a faculty member at Harvard Medical School and as a senior investigator with the TIMI Study Group, where she led international trials evaluating novel cardiovascular therapies and directed the genomics program. She currently is a director of Danaher Corporation. Dr. Mega received her B.A. from Stanford University, her M.D. from Yale University School of Medicine, and her M.P.H. from Harvard School of Public Health.
Morano held the role of Vice President, Business Development and Strategic Operations at Johnson & Johnson MedTech from 2020 through February 2023. Prior to that, she served as Vice President, Business Development, Johnson & Johnson Medical Devices, beginning in 2012, with responsibility for licensing, acquisitions and divestitures for its Medical Devices Group. During her time at Johnson & Johnson, Morano also held several positions within six operating companies, primarily in the finance and business development functions, and as a member of the MedTech Leadership Team. She received her B.S. from Villanova University and her M.B.A. from Columbia Business School.
“We are pleased to expand our board of directors with two highly qualified executives from different sectors of the healthcare industry,” said Mike Mahoney, chief executive and chairman of the board, Boston Scientific. “Jessica and Susan are accomplished leaders passionate about advancing patient care and experienced in bringing innovative technologies to market, and we look forward to their contributions as board members as Boston Scientific continues to grow and meet our stakeholder commitments.”
Related Articles
-
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
-
“I am honored to welcome Thierry Bernard as the new chair of the AdvaMedDx Board. With his decades of experience, Thierry brings a clear vision of the work we can accomplish, and I look forward to working with him.”
-
The two new members bring more than 40 years of leadership and IT experience to the HUMA.AI advisory boards, following a recent round of funding and the introduction of new post-market surveillance technologies.
-
“Francis Medical has a powerfully simple and differentiated technology, supported by an outstanding team. I’m excited to add my knowledge and experience to the group and make a meaningful impact as we strive to bring this transformational technology to urologists…
